The cell viability and IC50 values of the cell lines decreased with increasing time after treatment with HSA NP-mediated tumor-targeted Dox/OA combination therapy Human Serum Albumin Nanoparticle-mediated tumor-targeted Doxorubicin/ OA combination therapy (Dox@HSA-OA). This evidence concerns the gene ALB and neoplasm.